Navigation Links
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
Date:7/8/2008

armasset.com">kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that Clevudine will not demonstrate any additive antiviral benefit in combination with tenofovir in the head-to-head study, the risk that Clevudine will not demonstrate superiority over Hepsera in Clevudine's ongoing Phase 3 registration study, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

Viread and Hepsera are registered trademarks of Gilead Sciences, Inc.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Receives Notice of Allowance
2. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
3. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
4. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
5. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
8. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
9. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
10. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LONDON , December 24, 2014 ... grow at an average rate of 8.1%. The US ... Hip, knee and spine surgeries are the common orthopedic ... they have a lower penetration. Increased number of product ... composites. Non-metallic orthopedic devices have gained popularity in the ...
(Date:12/24/2014)... , Dec. 23, 2014 Echo ... medical device company focused on skin permeation, continuous ... Scott W. Hollander has been appointed ... Hollander has more than 20 years of experience ... industries, and most recently served as Vice President, ...
(Date:12/24/2014)... -- ResMed (NYSE: RMD ) today announced its ... device manufacturer BMC Medical Co., Ltd. The ... below infringe ResMed,s patents, and entered an order prohibiting BMC ... the United States : , iVolve nasal ... nasal pillows mask , iVolve full face mask ...
Breaking Medicine Technology:Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... Researchers will present,data at the International ... the Posit Science(R) Brain Fitness Program(TM),improves mental ... a condition associated with chemotherapy that results ... by impairing concentration and the,ability to make ...
... Feb. 7 BioNumerik Pharmaceuticals, Inc.,today announced ... global Phase III,clinical trial of BioNumerik,s anticancer ... cancer patients. BioNumerik is,developing Karenitecin (also known ... in the camptothecin class of chemotherapy drugs. ...
Cached Medicine Technology:Neuroscientists Offer Hope for Breast Cancer Patients Suffering From 'Chemobrain' 2BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R) 2BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R) 3
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... The click strand woven bamboo flooring ... the business announces a click strand woven bamboo ... 2015. , Click strand woven bamboo flooring replicates ... well-known brand in the bamboo industry. It promises ... bamboo flooring supplier. , “We are happy to ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. TS-1 is an anti-cancer drug which is typically ... and is also used for treating gastric cancer and ... otastat potassium. The drug was first approved in 1999 ...
(Date:12/25/2014)... 26, 2014 “Every three months the trends ... A-line sweetheart evening dress will be one of the hottest ... of Yunx.co.uk says. Today, the company releases 26 A-line sweetheart ... to 80% off. , “We are trying our best ... with our latest designs. Along with affordable prices, we provide ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... 700,000 for each of the 2011 prizes, of which CHF ... CHF 100,000 for their personal use. The prize ... be of considerable significance for medicine. Stefan Jentsch is ... his work on small protein modifiers and their role in ...
... HealthDay Reporter , TUESDAY, Jan. 25 (HealthDay News) ... research finds. Patients with ischemic stroke (involving a blood ... medication and survive if treated at one of these specialty ... published in the Jan. 26 issue of Journal of ...
... Reporter , TUESDAY, Jan. 25 (HealthDay News)-- Prolonged exposure to ... aged 65 and older, a new Danish study finds. ... of road noise, a person,s risk of having a stroke ... that did not translate into a statistically significant risk, but ...
... conducted at Sahlgrenska University Hospital in Gothenburg and at ... of 18 and 65. Half the group was randomly ... half to maintain their usual lifestyle. Both groups ... group increased their physical activity on their own, but ...
... , MONDAY, Jan. 24 (HealthDay News) -- The ... cyclists or pedestrians moving around them isn,t necessarily the result ... a heightened awareness of background movement, a new study from ... person, a part of the brain called the medial temporal ...
... past for children with ACL tears because of the possible damage ... life. With this new technology, surgeons can actually see ... knee, and can safely position the tunnels where they will place ... Medicine Center, and colleagues in the laboratory of Allen R. Tannenbaum, ...
Cached Medicine News:Health News:2011 Louis-Jeantet Prize for Medicine 2Health News:2011 Louis-Jeantet Prize for Medicine 3Health News:2011 Louis-Jeantet Prize for Medicine 4Health News:2011 Louis-Jeantet Prize for Medicine 5Health News:'Stroke Centers' Providing Better Care, Study Finds 2Health News:'Stroke Centers' Providing Better Care, Study Finds 3Health News:Loud Road Noise Linked to Stroke in Older Adults 2Health News:Loud Road Noise Linked to Stroke in Older Adults 3Health News:3-D MRI helps kids with ACL tears -- surgery without harming the growth plate 2
... Indications include painful arthritic deformity of ... the subtalar joint, failed fusion of ... tibial plafond and/or talus where reconstruction ... ankle joint combined with severe arthritic ...
The Buechel-pappas™ Total Ankle Replacement is a time-tested system which is the result of more than twenty years of development, clinical investigation, and use. The components have been avai...
... In 1985, the worlds first ... by Howmedica Osteonics as a means ... wire for trochanteric reattachment procedures. Today, ... papers demonstrating clinical successes, the Dall-Miles™ ...
... The Minimally Invasive Hip Instruments ... THA through a mini-incision using ... set of instruments helps reduce ... invasive THA by optimizing exposure ...
Medicine Products: